The evidences of the meta-analyses of discovery and validation cohorts (P-value < 0.05, Table 1; Fig. 2) for the associations of ABCC8/KCNJ11 with anal carcinoma (odds ratio (OR) = 1.000 × 10− 4, per SD change of glucose-lowering drug target perturbation equivalent to 1 SD unit of HbA1c lowering; 95% confidence interval (95% CI): 0.0001–0.013; P-value = 0.0002), HCC (OR = 0.003; 95% CI: 2.000 × 10− 4-0.028; P-value < 0.0001), but elevated risks of ICC (OR = 73.520; 95% CI: 10.312–524.150; P-value < 0.0001), pancreatic cancer (OR = 15.058; 95% CI: 3.824–59.295; P-value = 0.0001). Here, KCNJ11 is linked to anal carcinoma.